Senrebotase

Drug Profile

Senrebotase

Alternative Names: AGN-214868; SXN 100323; TEM

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Health Protection Agency Porton Down
  • Developer Allergan
  • Class Bacterial toxins; Endopeptidases; Non-opioid analgesics; Recombinant proteins; Urologics
  • Mechanism of Action SNARE protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Postherpetic neuralgia
  • No development reported Overactive bladder

Most Recent Events

  • 14 Oct 2016 Allergan in-licenses RTGel™ technology from Urogen Pharma
  • 23 Jun 2015 No recent reports on development identified - Phase-II for Overactive bladder in USA, France and Netherlands (Intravesicular)
  • 23 Jun 2015 No recent reports on development identified - Phase-II for Postherpetic neuralgia in Czech Republic (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top